NASD · Healthcare · Biotechnology · Ireland
Prothena Corp Plc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Prothena is a clinical biotechnology company developing therapies for neurodegenerative and rare peripheral amyloid diseases caused by protein dysregulation. The company's pipeline includes programs addressing Parkinson's disease, ATTR amyloidosis, Alzheimer's disease, and amyotrophic lateral sclerosis, utilizing its proprietary CYTOPE technology. Most of its clinical candidates are being developed through partnerships with large pharmaceutical companies.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Prothena Corp Plc stock.
Slightly overvalued: intrinsic value $8.00 per share, market price $8.47, margin of safety -5.9% (as of 2026-10-30).
A 2.4x revenue multiple, discounted for its losses, values the shares at $8.00; the price of $8.47 is 6% above that value.
Leak Score: 33/100 on 8 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
20 more in this industry show a wider margin of safety.
PRTA is slightly overvalued (as of the 2026-10-30 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $8.00; the price of $8.47 is 6% above that value.
$8.00 per share (as of the 2026-10-30 close), against a market price of $8.47. That is a margin of safety of -5.9%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
33 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.